Diamyd Medical AB (publ) (DMYDB) Earnings Call Transcripts

Diamyd Medical AB (publ)'s Latest Earnings Call - March 30, 2026

In the Q1 2026 earnings call, Diamyd Medical AB reported disappointing interim results from its Phase III trial of the Retogatein investigational therapy, revealing a statistically significant lack of efficacy and potential trial futility. The trial, which involved 174 patients over 15 months, showed 'basically no effect at all' across all subgroups, contrary to previous findings. Management emphasized the need for a thorough analysis to understand these unexpected results, which could have severe implications for the company's future and stock performance, leading to a significant drop in share price, down 80-90%.

Reported metrics

Guidance from management

Management has not provided specific guidance on future trial outcomes but emphasized the importance of understanding the current data before making any decisions regarding the trial's continuation.

What management said

Yes. And again, in the press release, we mentioned -- obviously, it's a very high level, but we said that we don't see any observable effect anywhere, including in prespecified subgroups, which also includes the potential super responder group. And this is -- again, these findings are what makes this especially surprising given all the previous data and experience.

And I'll say the Board and management of diabetes, many of them either have type 1 or have loved ones with them. So this is -- this remains and is always a focus that we're doing efforts that not only help the community, the global community. Type 1 diabetes is a global disease, but we're also doing it to help our loved ones. And so there's no question that this group is passioned about where it's going. And we will ...

What analysts pressed on

Analysts expressed concerns about the unexpected trial results and the implications for the company's future. There were questions regarding the potential reasons for the lack of efficacy and how this might affect investor confidence moving forward.

Main topics on the call

• Trial Results Disappointment — The interim readout from the Phase III trial indicated 'futility,' suggesting a low likelihood of positive outcomes in the full readout expected in summer 2027. CEO Ulf Hannelius stated, 'there's a very low likelihood th...
• Lack of Efficacy Across Subgroups — Management reported 'no observable effect anywhere, including in prespecified subgroups,' which is particularly concerning given prior positive trends in earlier trials. This inconsistency raises questions about the vali...
• Future Analysis and Transparency — Management committed to a 'systematic stepwise approach' to analyze the data and ensure accuracy before making any rash decisions regarding the trial's continuation. They aim to be 'as transparent and communicative as po...
• Cash Position and Runway — Diamyd Medical has a cash position of approximately USD 40 million, providing a runway of 18 to 24 months at the current burn rate. This financial cushion is critical as the company navigates the fallout from the trial r...

Read the full Diamyd Medical AB (publ) transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 Diamyd Medical AB (publ) earnings call transcripts on record, spanning September 17, 2020 to March 30, 2026. Based on this history, Diamyd Medical AB (publ) reports annually. The most recent call on file is dated March 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DMYDB

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

5

First call

September 17, 2020

Most recent

March 30, 2026

Reporting cadence

annually